作者:Michael T. Davenport、Jordan A. Dickson、Matthew R. Johnson、Stephen Chamberland
DOI:10.1021/acs.jnatprod.9b00813
日期:2019.11.22
The first total synthesis of clavatadine B (2), a natural product found to be a selective human blood coagulation factor XIa inhibitor, is described. A convergent approach that exemplifies the advantages of direct, early stage guanidinylation provided an immediate clavatadine B precursor, which was assembled in an efficient manner using known synthetic precursors of the structurally related natural
描述了克拉瓦他定B(2)的首次全合成,该物质是一种天然产物,是一种选择性的人类凝血因子XIa抑制剂。融合方法证明了直接,早期胍基化的优势,提供了一种直接的克拉维他定B前体,该前体使用结构相关的天然产物克拉维他定A(1)的已知合成前体以有效的方式组装而成。全局脱保护仅需四个步骤即可从高纯酸内酯的已知衍生物(最长的线性序列,总收率75%)清洁地提供克拉维他定B。